Cosmax Nbt, Inc. (KOSDAQ:222040)
7,570.00
+780.00 (11.49%)
At close: May 11, 2026
Cosmax Nbt Revenue
In the year 2025, Cosmax Nbt had annual revenue of 287.48B KRW, down -9.59%. Cosmax Nbt had revenue of 73.98B in the quarter ending December 31, 2025, a decrease of -7.81%.
Revenue
287.48B
Revenue Growth
-9.59%
P/S Ratio
0.54
Revenue / Employee
560.39M
Employees
513
Market Cap
155.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 287.48B | -30.51B | -9.59% |
| Dec 31, 2024 | 317.99B | -15.65B | -4.69% |
| Dec 31, 2023 | 333.63B | 5.42B | 1.65% |
| Dec 31, 2022 | 328.21B | 38.86B | 13.43% |
| Dec 31, 2021 | 289.35B | 22.56B | 8.45% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| H.PIO | 258.19B |
| DongKoo Bio & Pharma | 242.69B |
| Kyung Dong Pharmaceutical | 196.27B |
| GC WellBeing | 164.68B |
| HYUNDAI BIOLAND | 130.51B |
| KOREA PHARMA | 87.60B |
| OPTUS Pharmaceutical | 87.16B |
| High Tech Pharm | 70.18B |